BioAffinity Technologies 2025 Annual Report: Key Investor Takeaways

Executive Summary

BioAffinity Technologies, Inc. (Nasdaq: BIAF), a biotechnology company with operations in San Antonio, Texas, has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This report reveals several critical developments and financial highlights that current and prospective shareholders must consider. The Company operates through its main entity and two wholly owned subsidiaries: OncoSelect^® Therapeutics, LLC, and Precision Pathology Laboratory Services, LLC (“PPLS”).

Key Financial Highlights

• Significant Capital Raised: BioAffinity raised approximately \$16.9 million in gross proceeds from equity transactions throughout 2025 to fund its operating activities. Notable transactions include:
  • October 2025 Registered Direct Offering: 720,000 shares of common stock at \$2.50 per share, raising about \$1.8 million in gross proceeds.
  • September 2025 Public Offering: 1,047,694 shares of common stock and pre-funded warrants to purchase up to 874,067 shares, with total gross proceeds of approximately \$4.8 million.
• Nasdaq Listing: The Company’s common stock (BIAF) and tradeable warrants are listed on The Nasdaq Stock Market LLC.

Key Strategic and Operational Updates

• Business Model and Growth: The Company is focused on the development and commercialization of diagnostic tests and potential therapeutic product candidates, with CyPath^® Lung as a flagship lung cancer diagnostic test.
• PPLS, the Company’s laboratory subsidiary, is highlighted as a crucial business unit, with risks and opportunities related to scaling operations and billing practices.

Risks and Forward-Looking Statements

BioAffinity’s management outlines a comprehensive list of forward-looking statements and associated risks, which are important for all investors to consider:

• Dependence on Additional Capital: The business plan relies heavily on the ability to secure additional financing. The report emphasizes that BioAffinity must raise further capital to continue as a going concern. Failure to do so could materially impact operations and shareholder value.
• Market Acceptance and Reimbursement: The Company’s success depends on convincing physicians of the benefits of its diagnostics and obtaining adequate reimbursement. If unsuccessful, this could lead to delays, additional expenses, and impact revenues.
• Regulatory Environment and Compliance: Compliance with healthcare laws and regulations is critical. Non-compliance could result in substantial penalties.
• Competition: The Company faces intense competition in the biotechnology and pharmaceutical industries, with rapid changes in the market for diagnostic tests and therapeutics.
• Technology, IP, and Operational Risks:
  • Risks related to protecting trade secrets and patents. Changes in patent law or non-compliance with patent requirements could harm the business.
  • Disruption of internal information technology systems and potential cybersecurity incidents.
  • Global climate change and related regulations may adversely affect operations.
• Economic and Geopolitical Factors: The Company notes that ongoing geopolitical tensions (e.g., Ukraine/Russia, China/Taiwan, Middle East), economic uncertainty, inflationary pressures, and any worsening of the global business environment could further exacerbate existing risks.

Risks Related to Common Stock and Warrants

• The market price of BIAF common stock may never exceed the exercise price of outstanding warrants, potentially impacting warrant holder value.
• Holders of warrants have no rights as stockholders until exercise.
• Provisions of outstanding warrants may limit holders’ ability to choose the judicial forum for disputes.
• The Company’s Certificate of Incorporation allows for “blank check” preferred stock, granting the Board authority to designate new share classes without stockholder approval.
• Certain charter and bylaw provisions could make an acquisition more difficult, which may affect the Company’s attractiveness to potential buyers or merger partners.

Other Material Matters

• PPLS (Precision Pathology Laboratory Services): If PPLS is unable to scale or manage its complex billing processes, its business could suffer, which would negatively affect consolidated results.
• Intellectual Property Risks: Inability to protect trade secrets or changes in patent law could impair competitive positioning.
• Regulatory Approvals: Failure to obtain or comply with approvals in the U.S. or abroad would limit the Company’s ability to commercialize products and realize their full market potential.
• Healthcare Policy Uncertainty: The impact of ongoing or future healthcare reform is unknown, adding uncertainty to future reimbursement and regulatory requirements.

Shareholder Implications & Potential Price Sensitivity

• Going Concern Risk: The need to secure additional funding is a significant risk factor. If the Company cannot raise new capital, operations and share value may be severely impacted.
• Equity Dilution: Recent and potential future equity raises may dilute existing shareholders, but are necessary for continued operations and growth.
• Regulatory, Competitive, and Operational Risks: Any adverse developments in these areas could result in significant share price volatility.
• Market Performance of BIAF: The share price is closely tied to the success of commercialization efforts, regulatory outcomes, and continued access to capital markets.

Conclusion

BioAffinity Technologies’ 2025 Annual Report highlights a year of significant capital raising and continued strategic focus on diagnostics and therapeutics, especially in lung cancer. However, the Company faces substantial risks related to its financial position, regulatory environment, competitive market, and operational execution. Investors should monitor future capital raises, regulatory events, and commercialization milestones closely, as these may materially affect the Company’s valuation and share price.

Disclaimer: This summary is provided for informational purposes only and does not constitute investment advice. Investors should review the full Annual Report and consult with their financial advisors before making any investment decisions. BioAffinity Technologies, Inc. faces numerous risks and uncertainties that may cause actual results to differ materially from those expressed or implied in forward-looking statements. The Company undertakes no obligation to update forward-looking statements except as required by law.

View bioAffinity Technologies, Inc. Historical chart here